Seeking Alpha

The FDA has approved a companion diagnostic test for Roche's (RHHBY.OB +0.5%) cancer drug...

The FDA has approved a companion diagnostic test for Roche's (RHHBY.OB +0.5%) cancer drug Tarceva, which detects certain gene mutations present in some non-small cell lung cancers. The cobas epidermal growth factor receptor, or EGFR, Mutation Test is the first FDA-approved companion diagnostic that detects a kind of gene mutation present in about 10% of non-small cell lung cancers, and, together with the drug, will be used as a first line treatment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|